GLP-1 drugs produce 5.7 kg weight loss in patients with inflammatory bowel disease | Research

The takeaway

A meta-analysis of 8 studies with 1,236 IBD patients found GLP-1 receptor agonists produced significant weight loss of 5.71 kg and BMI reduction of 2.18 kg/m², though evidence certainty was low to very low.

-5.71 kg in IBD patients
First meta-analysis shows GLP-1 drugs produce significant weight loss in inflammatory bowel disease patients, though evidence quality is low

What the researchers found

Pooled weight change: -5.71 kg (95% CI -9.56 to -1.86, p=0.01; I²=78%). Semaglutide subgroup: -5.59 kg (p=0.03; I²=80%). BMI change: -2.18 kg/m² (p<0.01; I²=81.1%). Evidence certainty: Low (weight) to Very Low (other outcomes).

Why it matters

IBD patients increasingly face obesity but have unique concerns—GI side effects of GLP-1 drugs may overlap with IBD symptoms, and effects on intestinal inflammation are unknown. This first meta-analysis provides preliminary safety and efficacy data for this population.

How the study worked

Systematic review and meta-analysis of PubMed, Embase, Scopus, Web of Science through October 2025. PROSPERO registered. 8 retrospective cohort studies, 1,236 patients. Random-effects model. GRADE assessment.

What this study cannot tell us

All 8 studies were retrospective. High heterogeneity. Low to very low evidence certainty (GRADE). IBD-specific outcomes (disease flares, inflammation) not well-reported. Small secondary outcome analyses.

How to read the evidence

Systematic review and meta-analysis of retrospective studies. GRADE: Low (weight) to Very Low (metabolic outcomes). Significant but imprecise estimates.

When this study was published

Published in 2025; literature through October 2025.

The bigger picture

As obesity becomes more common in IBD, clinicians need evidence on whether GLP-1 drugs are safe and effective in this population. This meta-analysis suggests they work for weight loss but highlights the need for larger, prospective studies before routine use.

Questions still open

Do GLP-1 drugs affect IBD disease activity or inflammation?
Are GI side effects of GLP-1 drugs more problematic in IBD patients?
Could GLP-1 anti-inflammatory effects benefit IBD independently of weight loss?

Common questions

Can people with Crohn's or colitis take GLP-1 drugs for weight loss?

This meta-analysis suggests GLP-1 drugs can produce meaningful weight loss in IBD patients. However, the evidence quality is low and there are concerns about GI side effects overlapping with IBD symptoms. If considering these drugs, close monitoring by both a gastroenterologist and prescriber is important.

Could GLP-1 drugs help or hurt inflammatory bowel disease?

The answer is not yet clear. GLP-1 drugs have known anti-inflammatory properties that could theoretically benefit IBD, but they also cause GI side effects that might worsen symptoms. This meta-analysis focused on weight loss rather than disease activity. More research is needed to understand the full impact on IBD.

Read the original research

Efficacy of GLP-1 receptor agonists on obesity and metabolic profile in patients with inflammatory bowel disease: a systematic review and meta-analysis.

BMC gastroenterology, 25(1), 878

View on PubMed ↗Publisher’s paper ↗

Citation

Shirmard, Fatemeh Ojaghi; Pourfaraji, Seyed Morteza; Omouri-Kharashtomi, Mahyaar; Amani, Arash. (2025). Efficacy of GLP-1 receptor agonists on obesity and metabolic profile in patients with inflammatory bowel disease: a systematic review and meta-analysis.. BMC gastroenterology, 25(1), 878. https://doi.org/10.1186/s12876-025-04496-5